[…] insulin icodec demonstrates superior reduction in HbA1c in combination with a dosing guide app versus once-daily basal insulin in people with type 2 diabetes in Onwards 5 phase 3a trial Bagsværd, Denmark, 3rd October 2022Novo Nordisk today announced headline results from the Onwards 5 phase 3a trial with once-weekly insulin icodec in people with type 2 diabetes. The Onwards 5 trial was a 52-week, open-label efficacy and safety treat-to-target trial investigating once-weekly insulin versus […] weiterlesen …